Effects of short-term and perioperative antiviral therapy on prognosis after hepatectomy for hepatitis B virus-related hepatocellular carcinoma
Research Square (Research Square)(2022)
Abstract
Abstract Background: Although the benefits of antiviral therapy against hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) have been proven, researchers have not confirmed the difference in outcomes among patients who receive short-term (at least 24 weeks) or perioperative antiviral therapy after liver hepatectomy for HBV-related HCC. Methods: A retrospective study of patients who underwent hepatectomy for HBV-related HCC at the First Affiliated Hospital of Xi'an Jiaotong University from January 2016 to June 2019 was conducted. Considering the history of antiviral therapy, patients were divided into perioperative (control group, n=108) and short-term antiviral therapy groups (n=108). Results: Baseline clinical and laboratory tests and tumor characteristics were compared between the two groups. The Kaplan–Meier analysis showed a significant difference in overall survival (P<0.0001) and disease-free survival (P=0.035) between the two groups. Multivariate analysis demonstrated that short-term antiviral treatment was independently related to enhanced survival outcome in OS (hazard ratio =0.27; 95% confidence interval= 0.08–0.88, P=0.030). Conclusions: In patients with HBV-related HCC, receiving short-term antiviral therapy for at least 24 weeks resulted in enhanced outcomes.
MoreTranslated text
Key words
perioperative antiviral therapy,hepatocellular carcinoma,hepatectomy,short-term,virus-related
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined